If you're interested in broad exposure to the Large Cap Growth segment of the US equity market, look no further than the Vanguard Russell 1000 Growth ETF (VONG) , a passively managed exchange traded fund launched on September 22, 2010.The fund is sponsored by Vanguard. It has amassed assets over $30.51 billion, making it one of the largest ETFs attempting to match the Large Cap Growth segment of the US equity market.Why Large Cap GrowthLarge cap companies typically have a market capitalization above $10 bil ...

Core Insights - The Invesco S&P MidCap 400 Pure Growth ETF (RFG) is designed to provide broad exposure to the Mid Cap Growth category, launched on March 1, 2006 [1] - RFG aims to match the performance of the S&P MidCap 400 Pure Growth Index, which focuses on securities with strong growth characteristics [5] Investment Strategy - Smart beta ETFs, like RFG, utilize non-cap weighted strategies to potentially outperform traditional market cap weighted indexes [3] - Various methodologies exist within smart beta, including equal-weighting and fundamental weighting, though not all guarantee superior results [4] Fund Details - RFG is managed by Invesco and has assets totaling approximately $292.57 million, categorizing it as an average-sized ETF in its segment [5] - The ETF has an annual operating expense ratio of 0.35%, which is competitive within its peer group, and a 12-month trailing dividend yield of 0.44% [6] Sector Exposure - The ETF has a significant allocation in the Industrials sector, comprising about 30.6% of the portfolio, followed by Consumer Discretionary and Healthcare [7] - The top 10 holdings represent approximately 21.11% of total assets, with Carpenter Technology Corp (CRS) being the largest at 2.9% [8] Performance Metrics - As of August 21, 2025, RFG has returned approximately 2.55% year-to-date and 4.19% over the past year, with a trading range between $39.08 and $53.39 in the last 52 weeks [10] - The fund has a beta of 1.08 and a standard deviation of 21.65% over the trailing three-year period, indicating medium risk [10] Alternatives - Other ETFs in the Mid Cap Growth space include Vanguard Mid-Cap Growth ETF (VOT) and iShares Russell Mid-Cap Growth ETF (IWP), with VOT having $17.38 billion in assets and IWP $19.96 billion [12] - VOT has a lower expense ratio of 0.07%, while IWP's is 0.23%, making them potentially more attractive options for cost-conscious investors [12]

Graphene Manufacturing Group Ltd. Announces Upsize of Bought Deal Public Offering for Gross Proceeds of C$6 MillionAugust 21, 2025 7:15 AM EDT | Source: Graphene Manufacturing Group Ltd.Brisbane, Queensland, Australia--(Newsfile Corp. - August 21, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that as a result of strong investor demand, the Company has increased the size of its previously announced "bought deal" public offer ...

Tel Aviv, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, is pleased to announce that its board of directors has resolved to commence the application process to list the Company’s ordinary shares, no par value (the “Ordinary Shares”) for trading on the Frankfurt Stock Exchange (“FSE”). The Company’s Ordinary Shares and public warrants will continue to trade on the Nasda ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whethe ...

David A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As an investor entrepreneur, David invests in stocks, bonds, options, ETFs, REITs, real estate, closed end funds and alternative investment funds such as hedge funds and private credit. With over 30 years’ experience in investing, David holds a Master of Science (MS) Degree in Finance, with a concentration in Investment Analysis, from Boston University, a Certificate in Financial Planning, and ...

Core Viewpoint - DiamiR Biosciences Corp. has received approval for its APOE Genotyping test from the New York State Department of Health, allowing it to offer this test through its accredited laboratory, which is a significant milestone for the company in expanding its diagnostic capabilities for brain health [1][3][4] Company Overview - DiamiR Biosciences is focused on developing innovative blood-based diagnostic tests for brain health and other diseases, with a particular emphasis on neurodegenerative conditions [1][8] - The company utilizes a proprietary platform technology that analyzes microRNA signatures in plasma for early detection and monitoring of brain health conditions [8] Regulatory Approval - The approval from the New York State Department of Health is part of the Clinical Laboratory Evaluation Program (CLEP), which is known for its stringent validation standards for laboratory-developed tests [2][3] - This approval enables DiamiR to provide its APOE Genotyping test using various biological samples, including blood and saliva, through licensed healthcare providers [1][2] APOE Testing Significance - The APOE test identifies genetic variants linked to the risk of late-onset Alzheimer's disease, with the APOE ε4 allele being the strongest known genetic risk factor [4] - Individuals with one copy of the APOE ε4 allele have a 3-4 times higher risk of developing Alzheimer's, while those with two copies have an 8-12 times higher risk compared to non-carriers [4] Merger Announcement - DiamiR Biosciences and Aptorum Group Limited have entered into a definitive agreement for an all-stock merger, which is expected to close in the fourth quarter of 2025, subject to stockholder approval [6] - Upon completion of the merger, DiamiR will become a wholly-owned subsidiary of Aptorum Group [6] Broader Diagnostic Portfolio - DiamiR's diagnostic portfolio includes tests for monitoring brain health through the analysis of circulating brain-enriched and inflammation-associated microRNAs in blood plasma [5]

Core Insights - Kraig Biocraft Laboratories, Inc. has fully operationalized its second production rearing center in Southeast Asia, enhancing its spider silk technology capabilities [1][5] - The establishment of two active production facilities allows for continuous rearing cycles of specialized recombinant spider silk silkworms, increasing resilience and scalability [2][5] - The company has expanded its breeding program with new genetic lines, which are expected to improve production efficiencies [3][5] Production and Operations - The dual-site capacity is designed to avoid past bottlenecks and create efficient redundancy, marking a significant advancement in sustained production [4][5] - Active teams are working with established parental lines for BAM-1 production hybrids and three additional parental lines introduced earlier this summer [3][5] Strategic Goals - The operational milestone of the second rearing center strengthens the foundation of the company's spider silk production platform, essential for scaling production and meeting market demand [5] - The company aims to diversify its breeding program and accelerate the development of next-generation hybrids to cater to growing demand from various markets and industries [5]

Core Insights - Veeva Systems is hosting the Veeva R&D and Quality Summit on September 3-4, 2025, in Boston, featuring leaders from major biopharmaceutical companies like BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer to discuss advancements in clinical, regulatory, safety, and quality processes [1][5] Group 1: Event Highlights - The summit will showcase over 100 sessions focused on the latest advancements in life sciences, including strategies for accelerating development and manufacturing by connecting systems and processes [3] - Key topics include improving trial oversight and collaboration among sites, sponsors, and CROs [4] Group 2: Innovations and Technologies - Veeva will highlight its advancements in software, data, and business consulting, particularly the integration of Veeva AI into the Vault Platform, which provides secure access to data and workflows [2] - The event will feature discussions on how customers can leverage Veeva AI to create custom agents tailored to their needs [2] Group 3: Industry Engagement - The summit aims to foster an environment of openness where industry leaders can share experiences and ideas to expedite the delivery of medicines to patients [5] - More than 2,000 attendees are expected, all of whom are life sciences professionals [6] Group 4: Company Overview - Veeva Systems is recognized as a global leader in cloud software for the life sciences industry, serving over 1,000 customers, including large biopharmaceutical companies and emerging biotechs [7]

Core Viewpoint - The company is on track to achieve breakeven in Q4 2025, supported by improved vehicle margins and a solid delivery scale, despite increased R&D guidance in the second half of 2025 [1][4]. Group 1: Financial Performance - In Q2 2025, vehicle sales increased by 17.5% QoQ to RMB16.9 billion, driven by an improved product mix and a rise in average selling price (ASP) by 7.1% QoQ to RMB164,000 [2][3]. - The vehicle margin expanded significantly from 10.5% in Q1 to 14.3% in Q2, aided by an optimized product portfolio and cost-cutting measures [3]. - Non-GAAP net losses narrowed from RMB426 million in Q1 to RMB385 million in Q2, exceeding expectations [4]. Group 2: Delivery and Production Guidance - The company guided for Q3 2025 sales volume of 113,000 to 118,000 units, aligning with forecasts for average monthly sales of 38,000 to 41,000 units [5]. - The company anticipates a robust year in 2026 with a higher number of new and revamped models, including the introduction of two SUV models in the MONA series [5]. Group 3: Technological Developments - The CEO outlined a roadmap for the growth of the robotics business, including plans for mass production of L4 autonomous driving vehicles by 2026 and humanoid robots in the second half of 2026 [6]. - The company is also exploring external supply opportunities for its self-developed AI Turing chip, which could diversify revenue streams and enhance its technological leadership [6]. Group 4: Valuation and Forecasts - The sales volume forecast for 2025 has been slightly revised down to 460,000 units, while the 2026 delivery forecast has been increased to 630,000 units [7]. - Revenue forecasts for 2025 and 2026 have been adjusted to RMB82.5 billion and RMB118.1 billion, respectively, reflecting the updated sales volume forecasts [8].